Westend Capital Management’s Lakewood-Amedex Biotherapeutics LABT Stock Holding History
Bought
Maintained
Sold
Other funds holding LABT
Westend Capital Management's LABT Position: Q3 2026 in Review
Westend Capital Management opened a new position in Lakewood-Amedex Biotherapeutics (LABT) in Q3 2026: 3,179 shares worth $3.04K. The stake represents ﹤0.01% of the portfolio and ranks #175 among its holdings.
7 funds tracked by Wall St. Rank hold LABT as of Q3 2026.
- Westend Capital Management held 3,179 shares of Lakewood-Amedex Biotherapeutics worth $3.04K as of Q3 2026.
- Lakewood-Amedex Biotherapeutics was a new Westend Capital Management position in Q3 2026.
- Lakewood-Amedex Biotherapeutics made up ﹤0.01% of Westend Capital Management's portfolio in Q3 2026, its #175 holding.
- 7 funds tracked by Wall St. Rank held Lakewood-Amedex Biotherapeutics as of Q3 2026.
Based on Westend Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.